Larry’s research for more than 60 years has focused on human cancer. He is a scientific visionary, best known for the concept of a mutator phenotype in cancer, which is the principle that tumors form and evolve resistance to therapy by virtue of their tendency to acquire mutations at an accelerated rate. He has published extensively in the fields of molecular biology, biochemistry, fidelity of DNA replication, creation of artificial enzymes, and Duplex Sequencing. Dr. Loeb graduated from The City College of New York, received an MD degree from New York University, a Post-Doctoral fellowship at NIH, and a PhD from The University of California Berkeley. He is a professor in the Departments of Pathology and Biochemistry at the University of Washington where he served as director of the MD/PHD program for 23 years. He is past president of The American Association of Cancer Research, The Environmental Mutagen Society and a fellow of American Academy of Arts and Sciences.